While rs2275913 acts like a volume dial at the IL-17A promoter — controlling how much mRNA is produced when T cells activate — rs3748067 works at the other end of the gene, in the 3' untranslated region (3'UTR)¹¹ 3' untranslated region (3'UTR)
the section of mRNA after the protein-coding sequence, which contains binding sites for microRNAs and other regulatory molecules that control how much protein is ultimately made. Together, these two variants shape the IL-17A Th17 axis through complementary but distinct mechanisms.

The Mechanism

The rs3748067 variant lies at position c.*1249 in the IL17A 3'UTR, placing it in a region where microRNAs (miRNAs)²² microRNAs (miRNAs)
small non-coding RNA molecules that bind to mRNA 3'UTRs and suppress protein translation or trigger mRNA degradation regulate IL-17A protein output. The common C allele is associated with higher IL-17A protein levels in population studies — this may reflect impaired miRNA-mediated suppression at this site. A parallel study identified that pri-miR-938, which targets the IL17A 3'UTR, is associated with gastric cancer susceptibility through this same regulatory region, suggesting that 3'UTR variants and their miRNA regulators act together on IL-17A expression.

Unlike the promoter variant rs2275913, which has a well-characterized NFAT-binding mechanism, the exact miRNA responsible for 3'UTR regulation at rs3748067 has not been conclusively identified in published functional studies. The clinical associations across multiple diseases nevertheless suggest this 3'UTR position exerts meaningful regulatory influence on post-transcriptional IL-17A output.

This variant is part of the same IL17A linkage disequilibrium (LD) block³³ IL17A linkage disequilibrium (LD) block
a chromosomal region where SNPs tend to be inherited together as rs2275913, and the two variants are studied together in haplotype analyses. Despite being in partial LD, each variant retains independent information, and their combination is the most clinically studied unit for IBD susceptibility.

The Evidence

Ulcerative colitis (UC): The clearest evidence for rs3748067's clinical relevance comes from a Japanese case-control study of 202 UC patients and 475 controls (Kageyama et al., Clin Exp Med 2013)⁴⁴ (Kageyama et al., Clin Exp Med 2013). The haplotype combining rs2275913 AA (high-transcription promoter) and rs3748067 CC (unmodified 3'UTR, higher protein output) conferred a 3.38-fold UC risk compared to the low-risk haplotype (p=0.0007) — substantially higher than either variant alone. This synergy between promoter and 3'UTR variants illustrates how the two variants cooperate to amplify total IL-17A output.

Gastric cancer: A Japanese study examining rs3748067 in 337 gastric cancer cases and 587 controls found the T allele to be protective for intestinal-type GC (OR 0.511, 95%CI 0.272–0.962)⁵⁵ (OR 0.511, 95%CI 0.272–0.962), and inversely correlated with lymph node metastasis. However, a 2018 meta-analysis of 9 studies did not find a significant overall association⁶⁶ did not find a significant overall association, suggesting the gastric cancer finding may be population-specific.

Tuberculosis susceptibility: Two meta-analyses found the TT genotype associated with increased TB susceptibility in Asian populations (OR 1.36, 95%CI 1.03–1.79)⁷⁷ (OR 1.36, 95%CI 1.03–1.79). This apparent paradox — the T allele protective in cancer but harmful in infection — is consistent with IL-17A's dual biology: it drives pathological inflammation in autoimmune disease but provides essential protection against extracellular bacteria and fungi. If T allele reduces IL-17A output, users have lower Th17-mediated mucosal immunity against pathogens like Mycobacterium tuberculosis.

Coronary artery disease: A meta-analysis of 6 studies in 3,542 CAD cases and 3,212 controls found the TT genotype significantly protective in Asians (OR 0.37)⁸⁸ (OR 0.37), consistent with the idea that lower IL-17A output reduces vascular inflammation and atherosclerosis risk.

The collective evidence supports a model where the C allele at rs3748067 is associated with higher IL-17A protein levels, increasing risk for inflammatory and autoimmune conditions but potentially providing stronger Th17-mediated bacterial defenses, while the T allele correlates with lower IL-17A output, reducing inflammatory disease risk but decreasing Th17 immune protection.

Practical Actions

Because rs3748067 and rs2275913 operate through the same IL-17A protein, the practical interventions targeting the Th17 axis apply to both variants. For individuals carrying the CC genotype at rs3748067 — especially in combination with the rs2275913 A allele — the key priority is supporting natural regulation of IL-17A output.

Three interventions with evidence in the Th17 pathway are particularly relevant for the CC genotype: maintaining vitamin D3 status in the 40–60 ng/mL range (active vitamin D suppresses IL-17A transcription at the promoter level, complementing 3'UTR regulation), EPA/DHA omega-3 supplementation (EPA-derived prostaglandin D3 suppresses Th17 differentiation and IL-17A production), and multi-strain probiotics with Lactobacillus and Bifidobacterium strains that shift Th17/Treg balance.

For individuals with the TT genotype, the concern is less about inflammatory overactivation and more about potentially reduced Th17 immune defense. This is most clinically relevant in high-risk infectious environments or in individuals with known TB exposure.

Interactions

The most important interaction is with rs2275913⁹⁹ rs2275913
the IL-17A promoter variant at -197G>A that directly controls IL-17A transcription via NFAT binding. The rs2275913 AA + rs3748067 CC haplotype confers 3.38-fold UC risk — the highest IL-17A output state when both transcriptional (promoter) and post-transcriptional (3'UTR) mechanisms drive high protein production. Check your rs2275913 result alongside this variant for the full picture of your IL-17A axis activity.

IL17F rs763780¹⁰¹⁰ IL17F rs763780
a coding variant that reduces IL-17F bioactivity further modulates the Th17 output profile: individuals with high IL-17A output (rs2275913 AA, rs3748067 CC) and functional IL-17F have the highest combined Th17 cytokine activity.

PTPN22 rs2476601¹¹¹¹ PTPN22 rs2476601
a phosphatase variant that lowers the T cell activation threshold can compound autoimmune susceptibility in individuals who also carry high-IL-17A genotypes.

Cardiac myosin-binding protein C¹¹ Cardiac myosin-binding protein C
a large, modular protein encoded by MYBPC3 on chromosome 11p11.2 that integrates into the thick filament of the cardiac sarcomere, where it fine-tunes contraction by regulating myosin head positioning and cross-bridge cycling rate is the most frequently mutated protein in hypertrophic cardiomyopathy (HCM), accounting for roughly 40% of all genotype-positive cases. Among the hundreds of MYBPC3 pathogenic variants, the p.Arg502Trp missense mutation stands out: it is the single most recurrent HCM-causing point mutation identified in large European-descent cohorts, found in approximately 2.4% of all HCM patients screened. This variant is classified Pathogenic/Likely Pathogenic by 31 of 40 ClinVar submitters, with three-star expert review status.

The Mechanism

The MYBPC3 protein is built from ten immunoglobulin-like (Ig) and fibronectin-type III (FN3) domains²² immunoglobulin-like (Ig) and fibronectin-type III (FN3) domains
barrel-shaped protein folds numbered C0 through C10 from the N-terminus; the central C3-C6 region is one of the most common mutation hotspots in HCM. Arg502 sits on the surface of the C3 domain, positioned on a loop exposed to the cytoplasm. Unlike many HCM missense variants that destabilize the domain itself, the NMR structure of the Arg502Trp mutant C3 domain³³ NMR structure of the Arg502Trp mutant C3 domain
solved by Inchingolo et al. in 2014 using solution NMR spectroscopy, deposited as PDB 2MQ3 reveals preserved immunoglobulin-like folding — the domain remains structurally intact. Instead, replacing the positively charged, polar arginine with a bulky, hydrophobic tryptophan dramatically alters the electrostatic surface of C3. This change is predicted to disrupt binding between MYBPC3 and sarcomeric partner proteins that dock on this domain, corrupting the protein's regulatory role in cross-bridge cycling without affecting its incorporation into the sarcomere. The net result is an unrestrained, hypercontractile state characteristic of HCM: excessive myosin engagement, impaired relaxation, and ultimately cardiomyocyte hypertrophy, myofibrillar disarray, and interstitial fibrosis.

The Evidence

The foundational clinical study by Saltzman et al. (Circ Res, 2010)⁴⁴ Saltzman et al. (Circ Res, 2010) screened 1,414 unrelated HCM probands and identified Arg502Trp in 34 (2.4%) — the highest single-variant frequency in a large, unselected HCM cohort. Extending analysis to 17 families identified a total of 77 carriers. Family segregation yielded a calculated odds ratio of 11,000:1 for co-inheritance of the variant with HCM. Penetrance was age-dependent: roughly 50% of carriers lacked clinical evidence of HCM before age 45. Yet by age 50, approximately 30% of carriers had experienced a major adverse cardiac event (death, cardiac arrest, hemodynamically significant arrhythmia, or heart failure hospitalization). When Arg502Trp occurred alongside a second sarcomere gene mutation, 75% of carriers had a serious event before age 20 — a clinical severity approaching that of the most aggressive MYH7 mutations.

Haplotype analysis across all 17 families revealed at least 4 independent chromosomal backgrounds carrying the same mutation, indicating recurrent de novo origins rather than a single ancient founder. This explains why Arg502Trp appears broadly across European populations rather than clustering in a single ethnic group.

The 2024 AHA/ACC HCM guideline (Ommen et al., Circulation)⁵⁵ 2024 AHA/ACC HCM guideline (Ommen et al., Circulation) establishes the current management framework: all pathogenic sarcomere variant carriers require annual echocardiographic surveillance; symptomatic obstructive HCM should first receive beta-blockers or non-dihydropyridine calcium channel blockers, followed by mavacamten (FDA-approved 2022, Class I recommendation in 2024 guidelines) or disopyramide for refractory cases before considering invasive septal reduction therapy.

Practical Actions

For heterozygous Arg502Trp carriers, the practical priorities are: (1) establish baseline cardiovascular assessment with echocardiography, (2) commence annual surveillance even if currently asymptomatic — penetrance is age-dependent and over 50% of carriers will develop overt HCM by their sixth decade, (3) avoid competitive sport until HCM is excluded or appropriately risk-stratified, and (4) ensure all first-degree relatives are offered targeted genetic testing.

When obstructive HCM develops (resting or provoked left ventricular outflow tract gradient ≥30 mmHg), beta-blockers are the first-line treatment. Mavacamten, a cardiac-specific myosin inhibitor that directly reduces the proportion of force-generating myosin heads, is a guideline-endorsed second-line agent for obstructive HCM and operates upstream of the mutation by normalizing cross-bridge cycling — making it mechanistically well-suited for sarcomere protein variants including MYBPC3. Disopyramide added to beta-blockade is an alternative. Surgical septal myectomy at experienced HCM centres remains the reference standard for drug-refractory outflow obstruction.

ICD implantation is guided by formal sudden cardiac death (SCD) risk scoring (ESC HCM Risk-SCD calculator or AHA/ACC 5-year MACE estimate). A prior cardiac arrest, sustained ventricular tachycardia, family history of HCM-related SCD in first-degree relatives, maximal LV wall thickness ≥30 mm, non-sustained VT on Holter monitoring, and unexplained syncope are all established risk factors that should inform the shared decision regarding ICD.

Interactions

The clinical severity of MYBPC3 Arg502Trp increases substantially when a second pathogenic sarcomere variant is present (compound heterozygosity or double heterozygosity). Saltzman et al. reported that carriers of Arg502Trp plus a second sarcomere gene mutation had 75% major event rates before age 20 — indistinguishable from the most aggressive single-gene mutations. Any first-degree relative found to carry both this variant and an additional sarcomere pathogenic variant should be evaluated urgently by an HCM specialist. Other MYBPC3 pathogenic variants already in this database — including rs187830361 (Trp792Arg), rs193922385 (Arg177Cys), rs397514752 (Gly490Val), and rs36211723 (Asp770Asn) — represent independent HCM-causing mutations in MYBPC3; compound heterozygosity for two such mutations is rare but clinically severe.

Toll-like receptor 3 (TLR3)¹¹ Toll-like receptor 3 (TLR3)
TLR3 is the innate immune system's dedicated sensor for double-stranded RNA (dsRNA) — the molecular signature produced when RNA viruses replicate inside cells stands guard in endosomes and on cell surfaces, scanning for viral invaders. When TLR3 detects dsRNA, it triggers production of type I interferons (IFN-α/β)²² type I interferons (IFN-α/β)
Interferons are signaling proteins that put neighboring cells into an antiviral state, slowing viral spread and activating natural killer cells and cytotoxic T lymphocytes — the body's fastest antiviral alarm. The rs3775291 variant (c.1234C>T), which swaps leucine for phenylalanine at amino acid 412, turns that alarm down significantly. Carriers produce a structurally altered receptor that binds viral dsRNA at roughly half the affinity of the normal form.

This variant is remarkably common in Europeans — the T allele appears in about 34% of European blood donors, with roughly 13% of Europeans carrying two copies (TT). By contrast, the T allele is far rarer in African and East Asian populations (approximately 5% and 10% respectively), a pattern that likely reflects ancient differences in viral exposure history during human migration and settlement.

The Mechanism

The leucine-to-phenylalanine substitution occurs in TLR3's ectodomain³³ ectodomain
The extracellular portion of TLR3 that directly contacts dsRNA ligands, forming the binding interface — specifically in a loop region that contacts the dsRNA phosphate backbone. A landmark functional study found that the L412F mutation reduces TLR3's dsRNA-binding capacity to just 51% of wild-type levels⁴⁴ landmark functional study found that the L412F mutation reduces TLR3's dsRNA-binding capacity to just 51% of wild-type levels
Measured using cell-based binding assays with poly(I:C), a synthetic dsRNA mimic; protein expression and surface distribution were unaffected. Critically, the protein is made in normal amounts and traffics correctly — the defect is purely in binding affinity, not receptor availability.

Downstream consequences include reduced NF-κB activation⁵⁵ NF-κB activation
NF-κB is a master transcription factor that drives expression of hundreds of immune genes including cytokines, adhesion molecules, and antiviral effectors, reduced IFN-β production, and — as more recent work has revealed — impaired macroautophagy⁶⁶ macroautophagy
The cellular process of engulfing and digesting damaged organelles and intracellular pathogens; critical for clearing virally infected material. This autophagy impairment appears particularly important in severe viral infections, potentially slowing the cell's ability to dispose of viral particles.

The Evidence

The clinical consequences of half-normal TLR3 function play out differently across diseases, sometimes strikingly in opposite directions.

Viral infections — increased susceptibility: A meta-analysis of 18 case-control studies (3,118 cases and 4,368 controls) found the T allele associated with a 16% increase in overall infectious disease risk⁷⁷ meta-analysis of 18 case-control studies (3,118 cases and 4,368 controls) found the T allele associated with a 16% increase in overall infectious disease risk
Dominant model OR=1.16, 95% CI 1.04–1.28, p=0.004; diseases included hepatitis B/C, HIV, dengue, tick-borne encephalitis, herpes simplex virus, and Japanese encephalitis. However, results were geographically heterogeneous: in European studies the T allele was actually protective (OR=0.83), while Asian and American studies showed increased risk (OR=1.37 and 1.42 respectively). This likely reflects differences in which pathogens dominate in each region and how TLR3 interacts with other immune loci.

For herpes simplex encephalitis (HSE), rare but serious TLR3 pathway mutations explain approximately 5% of childhood HSE cases⁸⁸ rare but serious TLR3 pathway mutations explain approximately 5% of childhood HSE cases
Among 120 HSE patients studied, 6 (5%) had TLR3 mutations; affected children had 66% HSE recurrence vs 10% in the broader cohort. While rs3775291 is a common hypomorphic variant rather than a complete loss-of-function mutation, it exemplifies the principle that TLR3 pathway competence is non-redundant in the brain during primary HSV infection in children. Separate case studies have documented HSE in adults heterozygous for TLR3 mutations.

For HIV, the T allele appears protective in highly exposed Europeans — 80% of highly exposed HIV-seronegative intravenous drug users carried at least one T allele versus 55% in blood donor controls⁹⁹ 80% of highly exposed HIV-seronegative intravenous drug users carried at least one T allele versus 55% in blood donor controls
Study of 497 blood donors and highly exposed seronegative cohort; OR=0.25 for HIV seropositivity among T allele carriers, 95% CI 0.07–0.87. This paradox (less TLR3 function = better HIV resistance) may relate to HIV's ability to exploit TLR3 signaling for its own replication, making a less responsive receptor protective in this particular context.

Age-related macular degeneration — protective: Perhaps the most consistent finding is that the TT genotype protects against geographic atrophy (advanced dry AMD)¹⁰¹⁰ protects against geographic atrophy (advanced dry AMD)
Meta-analysis of 9 studies with 7,400 AMD cases and 13,579 controls; protective OR=0.88 in recessive model, specifically in Caucasians. The biological rationale is compelling: in the aging retina, TLR3 on retinal pigment epithelial cells responds to debris from dying photoreceptors, triggering inflammatory damage. Reduced TLR3 activation attenuates this harmful cycle, protecting vision. This is a case where weaker receptor function is genuinely beneficial.

Pulmonary sarcoidosis: Two independent Caucasian cohorts (Irish and American) found TLR3 L412F significantly associated with persistent clinical disease¹¹¹¹ Two independent Caucasian cohorts (Irish and American) found TLR3 L412F significantly associated with persistent clinical disease
Irish cohort: n=228 patients, 263 controls; American replication cohort: n=123 patients; fibroblasts from 412F-homozygous patients showed reduced IFN-β and dysregulated fibroproliferative responses. Impaired viral clearance may trigger granuloma formation that fails to resolve, locking the disease into a chronic state.

COVID-19: The L412F polymorphism emerged as a marker of COVID-19 severity, particularly in males¹²¹² a marker of COVID-19 severity, particularly in males
Association strengthened in male sub-cohorts; mechanistic link via impaired autophagy, which slows clearance of viral material. Among COVID-19 patients treated with hydroxychloroquine (which further impairs autophagy), L412F carriers showed significantly reduced 28-day survival (p=0.038), suggesting the autophagy pathway is specifically important in this context.

Practical Implications

The duality of this variant — harmful for some viral infections, protective for macular degeneration — means the practical guidance depends heavily on context. TT homozygotes have the strongest protection against AMD but the most reduced antiviral dsRNA sensing. CT heterozygotes sit in between: partially reduced TLR3 function with correspondingly intermediate risks and benefits.

For viral defense, the most actionable insight is vigilance around prevention — ensuring vaccinations are current, minimizing high-risk exposures, and seeking early medical care for neurological symptoms after herpes virus infections. For long-term eye health, TT carriers have a genuine genetic advantage that does not require any active management.

Interactions

TLR3 works within a broader innate immune network. TLR9 (rs352140) senses CpG-rich bacterial and viral DNA¹³¹³ TLR9 (rs352140) senses CpG-rich bacterial and viral DNA
TLR3 senses viral dsRNA; TLR9 senses microbial DNA — together they cover complementary pathogen signatures, while TLR4 (rs4986790) responds to bacterial endotoxin (LPS)¹⁴¹⁴ TLR4 (rs4986790) responds to bacterial endotoxin (LPS)
These three TLRs collectively provide pattern recognition for the major classes of microbial threats. Carriers of multiple hypomorphic TLR variants may have compoundly reduced innate immune surveillance, particularly relevant for individuals with TLR3 L412F combined with TLR4 Asp299Gly — both reduce first-line pattern recognition.

The rs5743305 variant (promoter region, −926bp) reduces TLR3 transcription and has been co-studied with rs3775291 — carriers of both variants showed the lowest anti-viral antibody responses in measles vaccine studies. rs3775290 (exon 4, Phe459Phe) is a silent SNP often studied alongside rs3775291 in haplotype analyses of TLR3.

The smell of fish is produced by trimethylamine¹¹ trimethylamine
TMA: a volatile, pungent amine produced when gut bacteria ferment choline, lecithin, and other dietary compounds containing trimethylamine precursors. In most people, TMA is rapidly oxidized to odorless trimethylamine N-oxide (TMAO) in the liver by the enzyme FMO3 — flavin-containing monooxygenase 3. When FMO3 fails, TMA accumulates in the bloodstream and is exhaled, sweated, and excreted in urine, producing the characteristic persistent fishy odor of trimethylaminuria²² trimethylaminuria
TMAU, also called fish odor syndrome or fish malodor syndrome; OMIM #602079.

rs3832024 is a 2-nucleotide deletion (c.591_592del) in the FMO3 coding sequence that causes a frameshift and an immediate stop codon at amino acid position 197 (p.Cys197_Asp198delinsTer). The FMO3 protein is 532 amino acids long; the resulting truncated protein of 196 amino acids retains none of the FAD-binding or catalytic domains required for TMA N-oxygenation activity. Expression studies of similar FMO3 truncation alleles confirm no detectable functional activity toward typical FMO3 substrates³³ no detectable functional activity toward typical FMO3 substrates
Yamazaki H et al. Stop codon mutations in FMO3 responsible for trimethylaminuria in a Japanese population. Mol Genet Metab, 2007. This is a complete null allele.

The Mechanism

FMO3 is the dominant TMA-oxidizing enzyme in adult human liver. It uses FAD⁴⁴ FAD
flavin adenine dinucleotide — the cofactor that FMO3 uses to transfer oxygen to TMA, requiring intact FAD-binding and NADPH-binding domains in the C-terminal two-thirds of the protein and NADPH to perform N-oxygenation of TMA to TMAO. The c.591_592del deletion shifts the reading frame at codon 197, producing a stop codon that truncates the protein well before the catalytic core. Homozygous individuals carrying two D alleles produce only non-functional FMO3 fragments, leaving TMA entirely unoxidized. The disorder follows autosomal recessive inheritance⁵⁵ autosomal recessive inheritance
both chromosomes must carry loss-of-function variants for full TMAU expression; single-copy carriers have sufficient residual FMO3 activity from the intact allele and do not develop the syndrome: one functional FMO3 copy is sufficient for adequate TMA clearance.

The Evidence

ClinVar classifies rs3832024 as Pathogenic⁶⁶ Pathogenic
VCV000225364.15 — 6 of 6 submitters agree; review status: criteria provided, multiple submitters, no conflicts. The variant is essentially absent from European, African, South Asian, and Latino populations in gnomAD (AF = 0) but reaches a minor allele frequency of ~0.26% in East Asian populations⁷⁷ ~0.26% in East Asian populations
gnomAD v4 Exomes: 0.00259 in East Asian; 0.00174 in Japanese-specific database (38KJPN 77,442 alleles), making it the most prevalent severe FMO3 loss-of-function allele in East Asian populations.

Most trimethylaminuria cases arise from compound heterozygosity⁸⁸ compound heterozygosity
carrying two different loss-of-function FMO3 alleles, one on each chromosome — for example, c.591_592del on one chromosome and a different pathogenic variant on the other rather than homozygosity for a single allele. Shimizu et al. identified⁹⁹ identified
Shimizu M et al. Genetic variants of FMO3 derived from Japanese subjects with trimethylaminuria. Drug Metab Pharmacokinet, 2019 multiple FMO3 frameshift and missense variants in Japanese TMAU patients, consistently demonstrating that affected individuals harbor biallelic loss-of-function combinations.

Practical Actions

The primary treatment for trimethylaminuria is dietary: restricting intake of TMA precursors (choline, lecithin, TMAO) reduces the substrate load that overwhelms absent FMO3 function. GeneReviews¹⁰¹⁰ GeneReviews
Phillips IR & Shephard EA. Primary Trimethylaminuria. GeneReviews, 2020 recommends restricting foods high in choline (eggs, liver, kidney, legumes, soya products, brassicas) and TMAO-containing seafood, and avoiding lecithin supplements. Brassicas additionally inhibit residual FMO3 activity through dietary indoles and should be restricted even if FMO3 is partially functional.

Riboflavin (vitamin B2) at pharmacological doses (30–40 mg, 3–5 times daily with food) is used to boost residual FMO3 activity in partial-loss-of-function genotypes. For complete null alleles like c.591_592del homozygosity, the benefit is theoretically limited, but riboflavin is still clinically tried. A case report by Manning et al.¹¹¹¹ A case report by Manning et al.
Manning NJ et al. Riboflavin-responsive trimethylaminuria. JIMD Reports, 2012 documented marked urinary TMA reduction and socially significant odor improvement with 200 mg/day riboflavin in a compound heterozygous patient, indicating meaningful residual FMO3 capacity in some biallelic combinations.

Interactions

The most important interaction for this variant is compound heterozygosity with other FMO3 loss-of-function alleles. The common mild-TMAU haplotype p.Glu158Lys + p.Glu308Gly¹²¹² p.Glu158Lys + p.Glu308Gly
encoded by rs2266782 and rs1736557 respectively; together they reduce FMO3 activity by ~30-40% (rs2266782 + rs1736557 in cis) causes transient or mild TMAU, particularly in infancy. Individuals who carry c.591_592del (D allele, rs3832024) on one chromosome and the E158K+E308G haplotype on the other will have clinically significant TMAU because neither allele produces full enzymatic function. This is a compound heterozygous configuration worth flagging in any user who carries the D allele at rs3832024 alongside variants at rs2266782 or rs1736557.

HLA-B27¹¹ HLA-B27
Human Leukocyte Antigen B*27 — a class I MHC molecule encoded in the highly polymorphic HLA region of chromosome 6, present in approximately 8% of Europeans and 60–90% of ankylosing spondylitis patients worldwide represents the single strongest genetic association with any common disease known to medicine — individuals carrying this allele face a roughly 60-fold increased risk for ankylosing spondylitis (AS) compared to non-carriers. Direct HLA typing is complex and expensive, but rs4349859 — a common intronic SNP located 41 kb centromeric of the HLA-B gene and 5.4 kb telomeric of MICA — serves as a highly accurate genetic proxy for European HLA-B27 subtypes, making it possible to infer HLA-B27 status directly from standard genotyping arrays.

The A allele of rs4349859 arose on a chromosome bearing HLA-B27 in an ancestor shared by nearly all European and some Asian HLA-B27 carriers. This ancient founder event means the A allele travels with HLA-B27 in strong linkage disequilibrium²² linkage disequilibrium
a statistical association between alleles at nearby loci that persists across generations because recombination has not yet broken apart the ancestral haplotype, allowing the SNP to stand in for direct HLA-B27 typing in research and clinical screening applications.

The Mechanism

rs4349859 is an intronic variant in MICA-AS1 (MICA antisense RNA 1), a non-coding RNA gene located between HLA-B and MICA in the MHC class I region. The SNP itself has no known functional consequence — it does not change any protein or alter gene expression. Its clinical relevance derives entirely from the haplotype it marks: the A allele at rs4349859 is a reliable indicator that the individual carries an HLA-B27 allele³³ HLA-B27 allele
most commonly HLA-B*27:05 in Europeans, the primary AS-associated subtype; also tags B*2702, B*2708, and B*2709 on the same chromosome.

HLA-B27 itself causes disease through several proposed mechanisms. The arthritogenic peptide hypothesis holds that HLA-B27 presents self-peptides (or microbial peptides with structural similarity to self) to CD8+ T cells, triggering an autoimmune cascade directed at joint tissues. Supporting this model, variants in ERAP1 — the enzyme that trims peptides before they are loaded onto HLA-B27 — affect AS risk exclusively in HLA-B27-positive individuals, directly implicating the peptide-HLA-B27 interaction in disease pathogenesis. A complementary hypothesis involves the spontaneous misfolding of HLA-B27 heavy chains into homodimers, which activate NK cells and innate lymphocytes independently of peptide presentation.

The Evidence

rs4349859 as HLA-B27 proxy. In the landmark epistasis study by Evans et al.⁴⁴ Evans et al.
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nature Genetics, 2011, rs4349859 was used as the HLA-B27 proxy across a discovery cohort of 1,787 British and Australian cases plus 4,800 controls and a replication cohort of 2,111 cases and 4,483 controls. The SNP achieved 98.0% sensitivity and 99.0% specificity for HLA-B27 in the European ancestry subset (538 cases and 741 controls with known HLA-B27 status). The dominant model (A allele present = HLA-B27 positive) was used throughout, with the study confirming that ERAP1 variants have no detectable effect on AS risk in rs4349859 GG individuals (presumed HLA-B27-negative), but powerfully modify risk in A-allele carriers.

Population prevalence. A comprehensive New Zealand population study of 1,220 Caucasian controls found rs4349859 genotype frequencies of GG: 90.7%, AG: 8.8%, AA: 0.4%, corresponding to an A-allele frequency of ~4.7%⁵⁵ corresponding to an A-allele frequency of ~4.7%, consistent with the approximately 8–9% HLA-B27 prevalence in Northern European populations (heterozygotes carry one A allele; both A alleles in homozygotes are rarer). Concordance with direct serological HLA-B27 typing was 98.7–100% in European-ancestry individuals. The SNP tags all major European AS-associated subtypes (B*2702, B*2705, B*2708) but does not tag African (B*2703) or most Asian subtypes (B*2704, B*2706, B*2707), limiting its utility to European-ancestry individuals.

HLA-B27 and AS risk. The overall odds ratio for AS given HLA-B27 positivity is approximately 60, the strongest common-variant disease association documented in human genetics. Despite this extraordinary OR, only 1–2% of HLA-B27-positive individuals develop AS in their lifetime⁶⁶ Despite this extraordinary OR, only 1–2% of HLA-B27-positive individuals develop AS in their lifetime
population attributable risk is nonetheless substantial because B27 prevalence is 8% in Europeans and 60-90% of AS cases carry B27. Risk rises to approximately 20% if a first-degree relative has AS. HLA-B27 accounts for approximately 25% of AS heritability, with 116 additional genetic loci contributing ~30% combined.

Practical Implications

Knowing your rs4349859 genotype provides a genetic proxy for HLA-B27 status without the need for traditional HLA typing. For GG individuals (no A allele), the probability of carrying HLA-B27 is below 2%; residual risk comes from rare B27-positive individuals whose HLA-B27 subtype is not tagged by this SNP. For AG individuals (one A allele), HLA-B27 positivity is overwhelmingly likely — approximately 90% of A-allele carriers in European populations are HLA-B27 positive. For AA individuals (two A alleles), HLA-B27 positivity is essentially certain, and these individuals likely carry two HLA-B27 alleles.

The clinical significance of HLA-B27 positivity depends heavily on context. In isolation, carrying HLA-B27 (A allele at rs4349859) means a modestly elevated lifetime risk of AS (~1–2% absolute) that rises substantially with additional genetic risk (ERAP1 variants) or family history. The most important implication is that inflammatory back pain symptoms in an HLA-B27-positive individual should be evaluated rapidly for axial spondyloarthritis, since early treatment with NSAIDs has disease-modifying effects on radiographic progression.

Interactions

rs4349859 × ERAP1 variants (rs26653, rs30187, rs10050860): Epistasis in ankylosing spondylitis. This is the defining interaction for the entire ERAP1 locus. Evans et al. 2011 demonstrated unequivocally that all ERAP1 AS associations are conditional on HLA-B27 status⁷⁷ Evans et al. 2011 demonstrated unequivocally that all ERAP1 AS associations are conditional on HLA-B27 status
ERAP1 SNPs show zero association with AS in HLA-B27-negative individuals (GG at rs4349859), while in HLA-B27-positive individuals (AG or AA at rs4349859), ERAP1 risk alleles confer 3–4-fold differences in AS risk. The combined interaction p-value was 7.3 × 10⁻⁶. This epistasis is mechanistically coherent: ERAP1 trims peptides that are subsequently loaded onto HLA-B27; HLA-B27 status determines whether the trimmed peptide repertoire reaches a disease-triggering threshold.

rs4349859 × rs12191877 (HLA-C*06:02 proxy): Co-occurring immune susceptibility. HLA-C*06:02 is the primary genetic risk factor for psoriasis. Individuals carrying both HLA-B27 (rs4349859 A allele) and HLA-C*06:02 (rs12191877 A allele) are at risk for both AS and psoriasis and face elevated risk for psoriatic arthritis, a spondyloarthritis subtype overlapping both conditions. ERAP1 variants interact with both HLA alleles, albeit through partially distinct mechanisms and peptide repertoires.

Your hunger, fullness, and metabolic rate are governed by a constant dialogue between hormones in the bloodstream and neurons in the hypothalamus. At the center of this dialogue sits SH2B1, an adaptor protein that amplifies the signals from two of the most critical metabolic hormones: leptin (the long-term satiety signal from fat cells) and insulin (the short-term glucose regulator from the pancreas). rs4788102 is an intronic variant in SH2B1 on chromosome 16p11.2 — part of a genomic region robustly linked to body mass index in multiple large genome-wide association studies¹¹ genome-wide association studies
Studies that simultaneously examine hundreds of thousands of genetic variants across the genome to identify which ones correlate with a trait like BMI across tens of thousands of people. The A allele at rs4788102 tags the risk-increasing haplotype at this locus.

The Mechanism

SH2B1 is an adaptor protein with SH2 and PH domains that integrates multiple upstream hormonal signals. In hypothalamic neurons, it binds to and activates JAK2²² JAK2
Janus kinase 2 — the kinase that is activated when leptin binds its receptor and initiates downstream signaling inside the neuron, the kinase immediately downstream of the leptin receptor. When SH2B1 binds phospho-Tyr813 of JAK2, it stimulates JAK2 kinase activity and recruits insulin receptor substrate 1 (IRS1), feeding the signal into the PI3-kinase pathway that ultimately suppresses appetite and elevates energy expenditure. Without SH2B1, even a normal leptin signal is poorly amplified — the neuron becomes functionally leptin-resistant even with intact receptor expression and normal circulating leptin levels.

A 2020 study³³ 2020 study
Jiang et al. Leptin receptor-expressing neuron Sh2b1 supports sympathetic nervous system and protects against obesity and metabolic disease. Nat Commun, 2020 identified an important circuit: SH2B1 in leptin-receptor-positive neurons activates the sympathetic nervous system and brown adipose tissue⁴⁴ brown adipose tissue
Specialized fat tissue that burns calories as heat rather than storing them — the thermogenic furnace that helps maintain body weight thermogenesis. Mice with SH2B1 deleted from leptin receptor neurons progressively develop obesity, insulin resistance, and fatty liver. The pathway extends further: a 2024 circuit-level study⁵⁵ 2024 circuit-level study
Li et al. SH2B1 Defends Against Energy Imbalance, Obesity, and Metabolic Disease via a Paraventricular Hypothalamus→Dorsal Raphe Nucleus Neurocircuit. Adv Sci, 2024 showed that SH2B1 in paraventricular hypothalamus (PVH) neurons projects to the dorsal raphe nucleus to suppress food intake, with optogenetic activation of this circuit reducing eating and SH2B1 deletion in PVH neurons causing obesity and metabolic disease in both sexes.

SH2B1 also potentiates insulin receptor signaling in peripheral tissues, enhancing IRS1 phosphorylation and protecting it from dephosphorylation — a role that extends its metabolic influence beyond the hypothalamus into muscle, liver, and pancreatic beta cells. The comprehensive mechanistic review⁶⁶ comprehensive mechanistic review
Rui L. SH2B1 regulation of energy balance, body weight, and glucose metabolism. World J Diabetes, 2014 describes how SH2B1 deletion in mice produces the full metabolic syndrome: leptin resistance, insulin resistance, hyperphagia, obesity, and type 2 diabetes.

rs4788102 itself is intronic and does not alter the SH2B1 protein. Its BMI association is attributed to linkage disequilibrium with the nearby functional missense variant rs7498665 (Ala484Thr), which lies in a conserved protein domain of SH2B1 and has been independently associated with serum leptin, body fat, and waist circumference.

The Evidence

The first genetic signal at the SH2B1 locus came from the landmark GIANT consortium GWAS, Willer et al. 2009⁷⁷ Willer et al. 2009
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature Genetics, 2009. Meta-analysis: Stage 1 n=32,000+; Stage 2 n=59,000+; total >91,000, which identified SH2B1 as one of six newly significant BMI loci (P < 5×10⁻⁸) and noted that it "maps near key hypothalamic regulators of energy balance" alongside MC4R, POMC, and BDNF. The association was confirmed in Speliotes et al. 2010⁸⁸ Speliotes et al. 2010
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010 in nearly 250,000 individuals.

Beyond BMI, Prudente et al. 2011⁹⁹ Prudente et al. 2011
The SH2B1 obesity locus is associated with myocardial infarction in diabetic patients and with NO synthase activity in endothelial cells. Atherosclerosis, 2011 found the A allele of rs4788102 associated with myocardial infarction in type 2 diabetic patients across three cohorts (OR 1.21, 95% CI 1.04–1.41, p=0.016), with the protective GG genotype preserving insulin-stimulated nitric oxide synthase activity in endothelial cells — a mechanism linking SH2B1 to vascular function. An association with HbA1c in non-diabetic young adults¹⁰¹⁰ HbA1c in non-diabetic young adults
Lange et al. Evidence for Association between SH2B1 Gene Variants and Glycated Hemoglobin. Ann Hum Genet, 2016; n=5,641 European Americans was also identified (P = 2.2×10⁻⁴), suggesting the locus modestly influences glucose metabolism even before diabetes develops. A 2017 GWAS interaction analysis found rs4788102-A associated with BMI in physically active individuals (beta = 0.031 kg/m², P = 1×10⁻⁹), confirming that physical activity does not nullify the genetic signal at this locus.

Not all studies show effects: the SH2B1 locus showed no association with abnormal glucose homeostasis in a European meta-analysis of ~93,000 individuals Prudente et al. 2013¹¹¹¹ Prudente et al. 2013
Nutr Metab Cardiovasc Dis, 2013, and no independent association with central obesity in Chinese children after correction for multiple testing. The BMI signal is most robust in Europeans and in large pooled analyses.

Practical Actions

The SH2B1 pathway governs two parallel defenses against weight gain: satiety amplification (hypothalamus → eat less) and thermogenesis activation (sympathetic nervous system → burn more). Risk allele carriers face reduced efficiency in both. This makes both sides of the energy equation relevant: strategies that enhance peripheral satiety hormone responses and strategies that support sympathetically-mediated thermogenesis are particularly targeted for this genotype.

The modest but established vascular signal at this locus — through impaired endothelial NOS activity — makes metabolic monitoring more important for A allele carriers, especially those with additional cardiometabolic risk factors.

Interactions

rs4788102 is in linkage disequilibrium with rs7498665 (Ala484Thr), the functional missense variant in SH2B1 that directly alters protein structure. The two SNPs are co-associated across multiple studies and likely tag the same functional haplotype.

SH2B1 sits biologically upstream of the leptin receptor effector pathway shared with LEPR rs1137101 (Gln223Arg). When the leptin receptor itself is impaired (rs1137101 risk genotype), the upstream signal is already reduced before it reaches SH2B1. When SH2B1 is reduced in effectiveness (rs4788102 A allele), even a normal receptor signal is poorly amplified. Carriers of risk alleles at both loci face compound impairment at two nodes in the same hypothalamic satiety cascade.

Within the broader GIANT consortium obesity loci — FTO (rs9939609), MC4R (rs17782313), GNPDA2 (rs10938397) — each operates through a distinct mechanism. SH2B1's contribution is specifically through leptin signaling amplification and brown fat thermogenesis, complementing FTO's adipocyte thermogenesis mechanism and MC4R's downstream appetite suppression role. GWAS evidence shows these loci have additive, not multiplicative, BMI effects.

The IL1B gene encodes interleukin-1 beta (IL-1β)¹¹ interleukin-1 beta (IL-1β)
IL-1β is a master pro-inflammatory cytokine produced primarily by activated macrophages; it triggers NF-κB signaling and coordinates broad inflammatory gene expression, one of the most potent drivers of peritoneal inflammation in the body. In endometriosis, IL-1β plays a central and well-documented pathogenic role: it is elevated in the peritoneal fluid of affected women, secreted at higher levels by peritoneal macrophages, and creates the inflammatory milieu that allows ectopic endometrial tissue to implant, survive, and expand. The rs4848306 variant sits 3,737 base pairs upstream of the IL1B transcription start site (in the promoter region), where it can influence how much IL-1β the body produces in response to inflammatory stimuli — including the monthly retrograde menstruation that seeds the peritoneum with endometrial fragments.

The Mechanism

rs4848306 maps to chromosome 2, position 112,840,530 (GRCh38), within the promoter region of IL1B. The IL1B gene is encoded on the minus strand of chromosome 2; the promoter variant is therefore read in the complement direction, with papers frequently describing this position using the coding-strand notation as IL-1B -3737. The reference allele on the plus strand is G (~61% globally); the alternate allele is A (~39%). Haplotype studies in schizophrenia genetics²² Haplotype studies in schizophrenia genetics
A field that has intensively studied IL1B promoter variants because neuroinflammation is central to psychosis pathophysiology; the same promoter logic applies to peritoneal inflammation in endometriosis establish that the G allele at rs4848306 is part of the haplotype associated with elevated IL1B mRNA expression, while the A allele (coding-strand T) predicts reduced IL1B transcriptional output. This makes rs4848306 a regulatory variant that fine-tunes the amplitude of the IL-1β inflammatory response.

IL-1β in the peritoneal cavity acts at multiple points in endometriosis pathogenesis: it promotes adhesion of ectopic endometrial stromal cells to mesothelial surfaces, stimulates vascular endothelial growth factor (VEGF)³³ vascular endothelial growth factor (VEGF)
VEGF drives the neovascularization that sustains implant growth production to vascularize nascent implants, activates matrix metalloproteinases for tissue invasion, and suppresses natural killer cell cytotoxicity that would otherwise clear ectopic cells. A promoter variant that drives higher IL-1β output — the G allele — would amplify each of these steps during the inflammatory cascade that follows retrograde menstruation.

The Evidence

Elevated IL-1β in the peritoneal environment of women with endometriosis is one of the most replicated findings in the field. Sikora et al. found higher peritoneal fluid IL-1β and elevated macrophage IL-1β secretion in women with endometriosis compared to controls⁴⁴ Sikora et al. found higher peritoneal fluid IL-1β and elevated macrophage IL-1β secretion in women with endometriosis compared to controls
Sikora J, et al. Pro-IL-1β and macrophage IL-1β secretion in endometriosis. Ginekologia Polska, 2016, with pro-IL-1β disproportionately elevated, suggesting increased inflammasome-driven IL-1 processing. A complementary study found that IL-1β and ICE (IL-1β converting enzyme) levels were significantly higher in endometriosis peritoneal fluid⁵⁵ IL-1β and ICE (IL-1β converting enzyme) levels were significantly higher in endometriosis peritoneal fluid
Sikora J, et al. IL-1β, IL-18 and ICE in endometriosis. Ginekologia Polska, 2012, implicating dysregulated cytokine maturation in disease progression.

Akoum et al. documented a specific imbalance between IL-1β and its decoy inhibitory receptor (IL-1R2) in endometriosis peritoneal fluid⁶⁶ Akoum et al. documented a specific imbalance between IL-1β and its decoy inhibitory receptor (IL-1R2) in endometriosis peritoneal fluid
Akoum A, et al. Imbalance between IL-1β and IL-1R2 in endometriosis. Journal of Reproductive Immunology, 2008, most pronounced in infertile patients, linking the defect in local IL-1 control directly to infertility risk. This biochemical finding is complemented by genetic evidence: Mier-Cabrera et al. showed that IL1B variants (the +3954 allele, rs1143634) were enriched in stage IV endometriosis cases compared to controls (OR 2.69)⁷⁷ Mier-Cabrera et al. showed that IL1B variants (the +3954 allele, rs1143634) were enriched in stage IV endometriosis cases compared to controls (OR 2.69)
Mier-Cabrera J, et al. TNF-α, IL-1β and IL1-Ra polymorphisms and endometriosis severity. BMC Women's Health, 2022, supporting IL1B genetic variation as a modifier of disease severity rather than merely a bystander.

For rs4848306 specifically, the direct endometriosis evidence is pathway-based rather than variant-specific: the A allele reduces IL1B promoter activity, and lower IL-1β production capacity would logically dampen the peritoneal inflammatory cascade. This is classified as emerging evidence — the pathway plausibility is strong, but genome-wide significant association data for rs4848306 in endometriosis cohorts is not yet published.

Practical Actions

The G allele at rs4848306 is associated with higher IL-1β promoter activity. In the context of endometriosis, where peritoneal IL-1β excess is a documented and replicated finding, GG homozygotes may carry a heightened inflammatory tone that could favor lesion establishment and progression. Because this is an emerging-evidence variant, actions should focus on monitoring and evidence-based lifestyle factors known to modulate the IL-1β/IL-1Ra balance — specifically, dietary omega-3 fatty acids, which suppress IL-1β production, and awareness of symptoms that suggest active peritoneal inflammation.

Interactions

IL1A rs6542095: The IL-1α cytokine (encoded by IL1A) shares the same receptor as IL-1β and operates in the same peritoneal inflammatory cascade. Women carrying both the IL1A rs6542095-C risk allele (elevated IL-1α susceptibility) and the IL1B rs4848306 GG genotype (elevated IL-1β promoter activity) may experience compounded peritoneal IL-1 signaling — two branches of the same inflammatory pathway simultaneously amplified.

IL1RN rs2234663 (IL1B VNTR): The interleukin-1 receptor antagonist (IL-1Ra) competitively inhibits both IL-1α and IL-1β signaling. The IL1RN intron 2 VNTR (rs2234663, IL-1RN*2 allele) has been associated with lower IL-1Ra production in some tissues. A compounded state of high IL-1β (GG at rs4848306) with low IL-1Ra (IL1RN*2 carrier) would represent maximal unchecked IL-1 signaling in the peritoneal cavity.

IL1B rs1143634 (+3954): This IL1B exon 5 synonymous variant is the most studied IL1B variant in endometriosis; the *2 allele was associated with OR 2.69 for stage IV endometriosis in the Mier-Cabrera 2022 cohort. The two variants tag different haplotypes within the IL1B locus and may independently contribute to IL-1β expression amplitude.

Endothelin-1 (ET-1) is one of the most potent vasoconstrictors in human physiology, acting through two receptor subtypes to control vascular tone, blood pressure, and cardiac remodeling. The endothelin receptor type A¹¹ endothelin receptor type A
EDNRA is a G protein-coupled receptor that mediates ET-1's vasoconstriction, smooth muscle proliferation, and aldosterone release effects binds ET-1 with high affinity on vascular smooth muscle cells, arterial walls, and cardiac tissue, triggering sustained vasoconstriction. The rs5335 variant sits in the 3' untranslated region (3'UTR)²² 3' untranslated region (3'UTR)
The 3'UTR is the section of mRNA after the protein coding sequence; it contains regulatory elements that govern mRNA stability, translation efficiency, and response to microRNAs of EDNRA, where it can influence how much receptor protein is produced without altering the receptor's amino acid sequence.

The Mechanism

The rs5335 G>C change at chromosome 4:147,542,688 (GRCh38) falls within the 3'UTR of the EDNRA gene transcript. Variants in this regulatory region can alter the binding affinity of microRNAs and RNA-binding proteins, changing the stability and translation efficiency of EDNRA mRNA. Evidence from Darrah et al. 2010³³ Darrah et al. 2010
EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity. Physiological Genomics. 2010 demonstrated that EDNRA polymorphisms, including rs5335, directly associate with EDNRA mRNA levels in smooth muscle cells and with differences in smooth muscle cell proliferation rates — establishing a direct molecular mechanism by which this 3'UTR variant influences vascular biology.

Higher EDNRA receptor expression on vascular smooth muscle cells increases sensitivity to circulating ET-1. Since ET-1 signaling through EDNRA drives sustained vasoconstriction and promotes vascular smooth muscle hypertrophy, genetically elevated EDNRA expression translates to higher vascular resistance and blood pressure. This mechanism is consistent with the clinical observations linking GG genotype to elevated diastolic blood pressure.

The Evidence

The foundational cardiovascular study for rs5335 was Rahman et al. 2008⁴⁴ Rahman et al. 2008
Common genetic variation in the type A endothelin-1 receptor is associated with ambulatory blood pressure: a family study. Journal of Human Hypertension. 2008, which established that naturally occurring genetic variation in EDNRA is associated with ambulatory blood pressure measurements in a family cohort — a study design that controls for shared environmental influences.

More directly, Zeng et al. 2019⁵⁵ Zeng et al. 2019
Associations of EDNRA and EDNRB Polymorphisms with Intracerebral Hemorrhage. World Neurosurgery. 2019 found that GG genotype carriers had significantly higher diastolic blood pressure than CG or CC carriers in intracerebral hemorrhage patients (91.69 vs 84.71 mmHg, p=0.004). This 7 mmHg difference in diastolic pressure is clinically meaningful — chronic diastolic hypertension is a major modifiable risk factor for stroke, heart failure, and renal disease.

Downstream cardiovascular consequences have been documented in multiple outcome studies. Ellis et al. 2012⁶⁶ Ellis et al. 2012
Association between endothelin type A receptor haplotypes and mortality in coronary heart disease. Personalized Medicine. 2012 found EDNRA haplotypes involving rs5335 associated with mortality differences in coronary heart disease patients. Zhang and Sui 2014⁷⁷ Zhang and Sui 2014
Effect of SNP polymorphisms of EDN1, EDNRA, and EDNRB gene on ischemic stroke. Cell Biochemistry and Biophysics. 2014 extended the association to ischemic stroke risk. Griessenauer et al. 2018⁸⁸ Griessenauer et al. 2018
Associations between endothelin polymorphisms and aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery. 2018 linked EDNRA variants to aneurysmal subarachnoid hemorrhage outcomes, vasospasm, and delayed cerebral ischemia — conditions where ET-1-mediated vasoconstriction plays a central pathological role.

In oncology pharmacogenomics, Kopeva et al. 2022⁹⁹ Kopeva et al. 2022
Anthracycline-induced cardiotoxicity in women without cardiovascular diseases. Acta Cardiologica. 2022 identified rs5335 as a molecular predictor of cardiotoxicity from anthracycline chemotherapy (drugs like doxorubicin), suggesting that EDNRA genotype influences how the heart responds to chemotherapy-induced endothelial stress.

Practical Implications

Your rs5335 genotype relates to how sensitively your vasculature responds to endothelin-1 signaling. GG homozygotes — who show elevated EDNRA expression and higher diastolic BP — benefit from earlier and more targeted blood pressure monitoring, particularly diastolic pressure tracking, and benefit more from interventions that modulate the endothelin pathway. Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) are approved drugs for pulmonary arterial hypertension that directly target EDNRA; your genotype may influence response to these agents.

Dietary nitrates (beetroot juice, leafy greens) and supplemental L-arginine support nitric oxide production in endothelial cells, partially counterbalancing ET-1-driven vasoconstriction. Magnesium is a natural calcium antagonist that reduces vascular smooth muscle responsiveness to vasoconstrictors including ET-1. Regular aerobic exercise downregulates endothelin sensitivity over time through shear-stress-mediated increases in eNOS expression.

Interactions

The endothelin signaling system involves both EDNRA and EDNRB receptors, which have opposing vascular effects: EDNRA drives vasoconstriction while EDNRB on endothelial cells promotes vasodilation via nitric oxide. The Zeng 2019 study examined both rs5335 (EDNRA) and EDNRB polymorphisms together. Variants in EDN1 (rs5370, Lys198Asn) affect circulating ET-1 levels and would interact with EDNRA receptor sensitivity variants — individuals with both elevated ET-1 production (EDN1 Lys198Asn) and increased EDNRA receptor sensitivity (rs5335 GG) may face compounded vasoconstriction drive.

The EDNRA rs5335 G allele also shows strong population stratification: it is common in Europeans (~60%) but rare in Africans (~27%), meaning population-specific haplotype contexts may modulate the blood pressure effect direction and magnitude.

Von Willebrand factor is the primary bridge between a damaged blood vessel wall and the platelet plug that stops bleeding. It circulates as a series of multimers of varying size; the largest, high-molecular-weight (HMW) multimers are the most haemostatically active because they unfurl under shear stress to capture platelets at injury sites. Size is regulated by ADAMTS13¹¹ ADAMTS13
A metalloprotease that cleaves VWF at the Tyr1605-Met1606 bond in the A2 domain, converting ultra-large multimers into smaller circulating forms. The rs61750579 variant encodes the Val1607Asp substitution²² Val1607Asp substitution
valine-to-aspartate change at position 1607, immediately C-terminal to the ADAMTS13 scissile bond — one of the most mechanistically direct causes of type 2A von Willebrand disease (VWD) identified to date.

The Mechanism

The A2 domain of VWF normally folds so that the Tyr1605-Met1606 scissile bond is buried and inaccessible to ADAMTS13 in the absence of mechanical force. When large shear stress stretches VWF at sites of high flow, the A2 domain transiently unfurls, exposing the cleavage site for regulated proteolysis. The Val1607Asp substitution introduces a charged aspartate residue immediately adjacent to this bond, destabilising the folded A2 domain and promoting a constitutively open conformation³³ destabilising the folded A2 domain and promoting a constitutively open conformation
structural studies using FRET constructs showed that most type 2A mutations — including those at the cleavage site — separate the domain's N and C termini without requiring applied force. The result is that ADAMTS13 can cleave VWF continuously, even without mechanical provocation. HMW multimers are selectively degraded, leaving only small multimers in circulation that are unable to support effective platelet adhesion under physiological shear conditions.

Hassenpflug et al. expressed all 13 known A2 domain VWD type 2A mutations in recombinant form⁴⁴ Hassenpflug et al. expressed all 13 known A2 domain VWD type 2A mutations in recombinant form
using a standardised proteolysis assay with ADAMTS13 at physiological concentrations and found that 11 of 13 mutants showed increased susceptibility to cleavage compared to wild-type VWF — a finding that mirrors the selective HMW multimer loss seen in patients' plasma. V1607D was among the mutations that increased proteolytic susceptibility. The biochemical outcome — accelerated cleavage — exactly accounts for the absent HMW multimers that define VWD type 2A on gel electrophoresis.

The Evidence

Type 2A VWD caused by the Val1607Asp variant is classified as pathogenic in ClinVar (VCV000000286)⁵⁵ pathogenic in ClinVar (VCV000000286)
Three independent submitters, with classification criteria provided; OMIM allelic variant 613160.0003. ClinVar records document the selective loss of HMW VWF multimers in individuals carrying this variant, consistent with ADAMTS13 hyperactivity at the mutant A2 domain.

Structural modelling by Pozzi et al.⁶⁶ Pozzi et al.
2012, Biophysical Chemistry showed that the Val1607Asp mutation — in contrast to oxidative modifications at the nearby Met1606 residue that impair cleavage — shifts the VWF-ADAMTS13 interaction toward accelerated proteolysis, producing a net haemorrhagic phenotype. The model correctly predicts the clinical observation that these patients bleed rather than clot.

Inheritance is autosomal dominant⁷⁷ autosomal dominant
one mutant allele is sufficient to produce disease, because VWF multimers assembled from a mixture of wild-type and mutant subunits are still hypersusceptible to ADAMTS13 if even one Val1607Asp subunit is incorporated. This distinguishes type 2A VWD from the recessive type 3 VWD — heterozygous carriers of V1607D have full clinical disease, not a silent carrier state.

Practical Actions

Diagnosis of VWD type 2A requires a panel of laboratory tests: VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo or VWF:GPIbR), factor VIII coagulant activity (FVIII:C), and VWF multimer analysis. The hallmark is a discordant VWF:RCo to VWF:Ag ratio below 0.6 (more activity loss than antigen loss), with absent HMW multimers on gel electrophoresis.

Desmopressin (DDAVP) releases stored VWF from endothelial Weibel-Palade bodies but is only partially effective in type 2A VWD. Atiq et al. found that only ~31% of type 2 VWD patients achieve complete desmopressin response⁸⁸ Atiq et al. found that only ~31% of type 2 VWD patients achieve complete desmopressin response
compared to 100% of type 1 VWD patients without VWF gene variants, and response is highly variant-dependent. For the V1607D mutation — where accelerated proteolysis rapidly degrades the released VWF — the haemostatic benefit from DDAVP is typically short-lived and incomplete. A formal DDAVP trial under clinical supervision is required to determine individual response before relying on it for procedures.

For bleeds and surgical prophylaxis where desmopressin is insufficient, plasma-derived or recombinant VWF concentrate (Vonvendi, Wilate, Humate-P) restores all multimer sizes and is the established treatment. Antifibrinolytic agents (tranexamic acid) are effective adjuncts for mucosal bleeding.

Interactions

ABO blood group independently modulates circulating VWF levels — blood group O reduces VWF by approximately 25% through increased ADAMTS13-mediated clearance. Carriers of V1607D who also have blood group O (tagged by rs505922) may have compounded VWF deficiency beyond what the genotype alone predicts.

The rs1800380 variant (VWF p.Arg854Gln, type 2N VWD) affects the factor VIII binding domain of VWF rather than the A2 domain; compound heterozygotes carrying both V1607D and R854Q would have combined quantitative, qualitative, and FVIII-transport defects, requiring specialist assessment. Other VWF A2 domain variants (rs61750630 and related exon 28 mutations) can co-occur in the same gene and produce compound phenotypes.

Deep inside the MHC class III region on chromosome 6 sits a single letter change that quietly alters how aggressively your immune system attacks your own tissues. CFB R32Q (rs641153) replaces an arginine with a glutamine at position 32 of complement factor B — a serine protease that is the lynchpin of the alternative complement pathway¹¹ alternative complement pathway
The alternative pathway runs continuously at low level, sampling surfaces for pathogens and damaged cells; unlike the classical pathway it requires no antibodies to activate. The result is a version of factor B that is less efficient at amplifying complement activation, reducing inflammatory damage in tissues exposed to chronic complement fire — most critically, the ageing retina.

The Mechanism

Factor B circulates as a zymogen. When it encounters C3b²² C3b
C3b is deposited on surfaces after complement activation and serves as an anchor; CFB binds C3b to form the proenzyme C3bB before cleavage by factor D, it binds and is cleaved by factor D into Ba (released) and Bb. The Bb fragment stays bound to C3b, forming the alternative pathway C3 convertase (C3bBb), which in turn cleaves many more C3 molecules in a powerful amplification loop. The Arg-32 residue sits in the Ba fragment at the C3b binding interface.

The Gln-32 substitution (the A allele, Q variant) reduces CFB's affinity for C3b by approximately fourfold compared with the common Arg-32 form. This means the proenzyme C3bB complex forms less readily, the C3 convertase assembles less efficiently, and the amplification loop runs at lower intensity. The consequence is a measurable dampening of alternative pathway activity — not an abolition (which would cause serious immunodeficiency) but a calibration that reduces bystander tissue damage when the pathway fires in settings like the ageing retinal pigment epithelium.

The Evidence

The R32Q protective association with AMD is one of the most robustly replicated findings in ocular genetics. Gold et al. (Nature Genetics, 2006)³³ Gold et al. (Nature Genetics, 2006)
Screened ~900 AMD cases and ~400 matched controls; identified the H7 haplotype first defined the H7 haplotype — a chromosomal block combining the C2 intron 10 variant (rs547154) and CFB R32Q (rs641153) — which reduced AMD risk with OR 0.45 (95% CI 0.33–0.61). This haplotype arises because the two variants are in very strong linkage disequilibrium (r² ≈ 0.92–0.96), meaning they are almost always inherited together.

Grassmann et al. (2011)⁴⁴ Grassmann et al. (2011)
Case-control study of 367 neovascular AMD cases and 251 controls with subsequent meta-analysis provided the mechanistic confirmation and largest effect size: meta-analysis across 2,600 individuals showed per-allele OR of 0.30 (p = 1.8 × 10⁻³¹) — one of the most statistically significant protective effects ever observed in a complex disease. The in vitro biochemistry confirmed fourfold reduced C3b affinity for the 32Q protein.

A meta-analysis of 15 published studies (Wang et al., 2013)⁵⁵ meta-analysis of 15 published studies (Wang et al., 2013) showed consistent protection across ethnicity: homozygous AA vs GG yielded OR 0.26 (95% CI 0.15–0.45); the dominant model (any A allele vs GG) yielded OR 0.49 (95% CI 0.40–0.59). Protection was observed in both Caucasians and Asians. The A allele is also associated with reduced risk of polypoidal choroidal vasculopathy, an AMD subtype common in Asian populations.

Beyond AMD, the alternative complement pathway's role in autoimmune tissue damage has led researchers to examine CFB variants in systemic lupus erythematosus (SLE). The 6p21 region harbours multiple SLE susceptibility signals, and reduced complement activation (as produced by R32Q) is biologically consistent with lower autoimmune inflammation; the companion intronic CFB variant rs1270942 shows strong SLE risk association (OR ~2.5), with the R32Q protective allele pointing in the opposite direction.

Practical Implications

Carrying the A allele (Gln-32) is a genuine genetic advantage: your alternative complement pathway runs with lower amplification, reducing chronic inflammatory damage to tissues prone to complement-mediated injury. The most clinically validated benefit is AMD protection. While AMD is a polygenic disease and no single variant eliminates risk, having one or two A alleles meaningfully shifts lifetime probability of developing late AMD — particularly the neovascular (wet) form, where complement-driven choroidal neovascularization is a central mechanism.

For the roughly 79% of people who carry only G alleles, AMD risk from this locus is at population baseline. Standard AMD-relevant lifestyle measures — not smoking, lutein-rich diet, UV protection, and regular eye exams after 60 — remain equally important regardless of genotype. The R32Q variant does not confer immunity and interacts with other complement variants (especially CFH Y402H, ARMS2, and C3) to determine individual AMD risk profiles.

Emerging complement inhibitors (including CFB-specific drugs like iptacopan and danicopan) are in advanced clinical trials for AMD and other complement-driven diseases. Interestingly, individuals with R32Q are essentially pharmacogenomic previews of what CFB inhibition achieves — suggesting the same pathway that confers genetic protection may respond particularly well or less well to therapeutic complement blockade, though this has not yet been formally studied.

Interactions

The strongest documented interaction is the H7 haplotype, where CFB R32Q (rs641153) co-occurs with C2 IVS10 (rs547154) in near-complete linkage disequilibrium. Because the two variants are almost always inherited together, the protective effect measured for each individually is largely the same haplotype block acting in concert — with C2 IVS10 reducing classical pathway convertase efficiency and CFB R32Q reducing alternative pathway convertase efficiency.

The protective effect of R32Q is most clinically meaningful when considered alongside CFH Y402H (rs1061170): a person who carries CFH risk alleles (higher AMD risk) and also carries CFB R32Q (lower AMD risk) sits at a partially buffered intermediate. Combined haplotype analyses⁶⁶ Combined haplotype analyses
Gold et al. 2006 showed that C2/CFB haplotypes combined with CFH variants predicted clinical outcome in 74% of AMD cases and 56% of controls. Similarly, C3 R102G (rs2230199) and ARMS2 A69S (rs10490924) add independent risk layers that interact with the complement inhibitory effect of R32Q.